Enhanced MDM2 oncoprotein expression in soft tissue sarcoma: Several possible regulatory mechanisms

Sarcoma

Volumn 1, Issue 1, 1997, Pages 23-29

  Pollock, Raphael E ^a,b   Lang, Aiquing ^a   El Naggar, Adel K ^a   Radinsky, Robert ^a   Hung, Mien Chie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

MDM2; Oncogene amplification; Soft tissue sarcoma

Indexed keywords

EID: 0001812125     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13577149778443     Document Type: Article

References (46)

1. Chen CY, Oliner JD, Zhan Q, et al. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci 1994; 91:2684-8.
2. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor. EMBO J 1991; 10:1565-9.
3. Finlay CA. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 1993; 13:301-6.
4. Barak Y, Oren M. Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J 1992; 11:2115-21.
5. Momand J, Zanbetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69:1237-45.
6. Price BD, Park SJ. DNA damage increases the levels of MDM2 messenger RNA in wt p53 human cells. Cancer Res 1994; 54:896-9.
7. Juven T, Barak Y, Zauberman A, et al. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 1993; 8:3411-16.
8. Barak Y, Juven T, Haffner R, et al. mdm2 expression is induced by wild type p53 activity. EMBO J 1993; 12:461-8.
9. Wu X, Bayle H, Olson D, et al. The p-53-mdm-2 autoregulatory feedback loop. Genes and Dev 1993; 7:1126-32.
10. Otto A, Deppert W. Upregulation of mdm-2 expression in meth A tumor cells tolerating wild-type p53. Oncogene 1993; 8:2591-603.
11. Xiao Z, Chen J, Levine AJ, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995; 375:694-8.
12. Martin K, Trouche D, Hagemeier C, et al. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995; 375:691-4.
13. Jones SN, Roe AE, Donehower LA, et al. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378:206-8.
14. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378:203-6.
15. Sheikh MS, Shao Z-M, Hussain A, et al. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 1993; 53:3226-8.
16. Reigenberger G, Reifenberger J, Ichimura K, et al. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS and MDM2. Cancer Res 1994; 54:4299-303.
17. Reigenberger G, Liu L, Ichimura K, et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53:2736-9.
18. He J, Reifenberger G, Liu L, et al. Analysis of glioma cell lines for amplification and overexpression of MDM2. Genes Chromosom Cancer 1994; 11:91-6.
19. Ebert M, Yokoyama M, Kobrin MS, et al. Increased MDM2 expression and immunoreactivity in human pancreatic ductal adenocarcinoma. Int J Oncol 1994; 5:1279-84.
20. Okita S, Tsutsumi M, Onji M, et al. p53 mutation without allelic loss and absence of mdm-2 amplification in a transplantable hamster pancreatic ductal adenocarcinoma and derived cell lines but not primary ductal adenocarcinomas in hamsters. Mol Carcinogenesis 1995; 13:266-71.
21. Landanyi M, Cha C, Lewis R, et al. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993; 53:16-18.
22. Lianes P, Orlow I, Zhang Z-F, et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 1994; 86:1325-30.
23. Tomonori H, Kinoshita H, Yamada H, et al. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst 1994; 86:1331-5.
24. Quesnel B, Preudhomme C, Oscier D, et al. Overexpression of the MDM2 gene is found in some cases of hematological malignancies. Br J Hematol 1994; 88:415-18.
25. Chilosi M, Doglioni C, Menestrina F, et al. Abnormal expression of the p53 binding protein MDM2 in Hodgkin's disease. Blood 1994; 84:4295-300.
26. Finnegan MDM, Goepel JR, Royds J, et al. Elevated levels of MDM-2 and p53 expression are associated with high grade non-Hodgkin's lymphomas. Cancer Letters 1994; 86:215-21.
27. Seller H, Amela-Neuschwander S, Villena-Heinsen C, et al. Antibodies against murine double minute-2 (mdm2) in sera of patients with various gynaecological diseases. Cancer Lett 1995; 96:111-15.
28. Corvi R, Savelyeva L, Breit S, et al. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. Oncogene 1995; 10:1081-6.
29. Riou G, Barrois M, Prost S, et al. The p53 and mdm-2 genes in human testicular germ-cell tumors. Mol Carcinogenesis 1995; 12:124-31.
30. Oliner JD, Kinzler KW, Meltzer PS, et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358:80-6.
31. Radinsky R, Kraemer PM, Raines MA, et al. Amplification and rearrangement of the Kirsten ras oncogene in virus-transformed BALB/c 3T3 cells during malignant tumor progression. Proc Natl Acad Sci USA 1987; 34:5143-7.
32. Pollock RE, Lang A, Luo J, et al. Soft tissue sarcoma metastasis from clonal expansion of p53 mutated tumor cells. Oncogene 1996; 12:2035-9.
33. Adesina AM, Nalbantoglu J, Cavenee WK. p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res 1994; 54:5649-51.
34. Poremba C, Yandell DW, Metze D, et al. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression. Oncol Res 1995; 7:331-9.
35. Kovar H, Auinger A, Jug G, et al. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 1993; 8:2683-90.
36. Kessis TD, Slebos RJ, Han SM, et al. p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. Am J Pathol 1993; 143:1398-405.
37. Preudhomme C, Quesnei B, Vachee A, et al. Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes. Leukemia 1993; 7:1291-3.
38. Waber PG, Chen J, Nisen PD. Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas. Cancer Res 1993; 53:6028-30.
39. Esteve A, Lehman T, Jiang W, et al. Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas. Mol Carcinogenesis 1993; 8:306-11.
40. Landers JE, Haines Ds, Strauss JF III, et al. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994; 9:2745-50.
41. Olson DC, Marechal V, Momand J, et al. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 proteins. Oncogene 1993; 8:2353-60.
42. Gudas JM, Nguyen H, Klein RC, et al. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin Cancer Res 1995; 1:71-80.
43. Oliner JD, Pietenpol JA, Thiagalingam S, et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362:857-60.
44. Leach FS, Tokino T, Meltzer P, et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53:2231-4.
45. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994; 54:794-9.
46. Florenes VA, Maelandsmo GM, Forus A, et al. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 1994; 86:1297-1302.